Our data have shown higher AR expression levels in AML cells; therefore, we hypothesized that androgen signaling might protect AML cells against chemotherapy hence AR blockers (enzalutamide or darolutamide) might reduce AML cell survival. The gene discussed is AR; the disease is acute myeloid leukemia.